Cologuard® includes three different biomarker analyses (KRAS mutations, NDRG4 and BMP3 methylation pattern, and occult hemoglobin) and proved superior to fecal immunochemical tests (FIT) in terms of CRC and advanced precancerous lesion detection.19 However, due to the restriction to three genes and stool specimens only, Cologuard® cannot accurately depict tumor heterogeneity. The gene discussed is KRAS; the disease is neoplasm.